Compare Logitech International SA (LOGI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Regeneron Pharmaceuticals Inc — how do they compare? Logitech International SA trades at $103.79 (market cap $15.18B), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.5× Logitech International SA's market cap, and Logitech International SA pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| LOGI | REGN | |
|---|---|---|
Market Cap | $15.18B | $83.19B |
Sector | Technology | Health |
52-Week High | $126.69 | $812.27 |
52-Week Low | $85.84 | $545.94 |
Enterprise Value | $13.52B | $77.90B |
Dividend Yield | 1.62% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $106.33, up 3.26% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue is projected to grow to $4.9B in 2026, with net income margin improving to 16.27%. The company faces near-term supply chain risks from a key semiconductor supplier shutdown, but strong demand in gaming and premium devices supports growth.
The outlook is mixed: solid fundamentals and analyst consensus target of $109.75 suggest upside, but supply constraints and mixed analyst ratings (26% Buy, 47% Hold, 26% Sell) indicate caution. Investors should weigh robust profitability against operational risks in the coming quarters.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
